Page 1960 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 113 Human Leukocyte Antigen and Human Neutrophil Antigen Systems 1737.e3

95. Moretta L, Moretta A: Killer immunoglobulin-like receptors. Curr 119. Marincola FM: Possible biases in referral pattern to NIH and their
Opin Immunol 16(5):626–633, 2004. effect on HLA association studies. J Immunother Emphasis Tumor
96. Middleton D, Williams F, Halfpenny IA: KIR genes. Transpl Immunol Immunol 19:384, 1996.
14(3–4):135–142, 2005. 120. Cormier JN, Salgaller ML, Prevette T, et al: Enhancement of cellular
97. Vilches C, Parham P: KIR: diverse, rapidly evolving receptors of immunity in melanoma patients immunized with a peptide from
innate and adaptive immunity. Ann Rev Immunol 20:217–251, MART-1/Melan A. Cancer J Sci Am 3(1):37–44, 1997.
2002. 121. Hopkins KA vLA, Tardiff GN, et al: Lymphocytoxocity testing. In In
98. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural Zachary AATG, editor: ASHI Laboratory Manual, ed 2, Lenexa, Kans,
killer cell alloreactivity in mismatched hematopoietic transplants. 1990, p 195.
Science 295(5562):2097–2100, 2002. 122. Sakaguchi K, Ono R, Tsujisaki M, et al: Anti-HLA-
99. Gagne K, Brizard G, Gueglio B, et al: Relevance of KIR gene poly- B7,B27,Bw42,Bw54,Bw55,Bw56, Bw67,Bw73 monoclonal antibod-
morphisms in bone marrow transplantation outcome. Hum Immunol ies: specificity, idiotypes, and application for a double determinant
63(4):271–280, 2002. immunoassay. Hum Immunol 21(3):193–207, 1988.
100. Falkenburg JH, Marijt WA, Heemskerk MH, et al: Minor histocompat- 123. Yunis EJWE, Amos DB: Observation of the CYNAP phenomenon. In
ibility antigens as targets of graft-versus-leukemia reactions. Curr Opin In Terasaki IP e, editor: Histocompatibility 1970, 1970, p 351.
Hematol 9(6):497–502, 2002. 124. Scornik JC, Brunson ME, Schaub B, et al: The crossmatch in renal
101. Klein CA, Wilke M, Pool J, et al: The hematopoietic system-specific transplantation. Evaluation of flow cytometry as a replacement for
minor histocompatibility antigen HA-1 shows aberrant expression in standard cytotoxicity. Transplantation 57(4):621–625, 1994.
epithelial cancer cells. J Exp Med 196(3):359–638, 2002. 125. Buelow R, Chiang TR, Monteiro F, et al: Soluble HLA antigens and
102. Jin P, Wang E: Polymorphism in clinical immunology – From HLA ELISA–a new technology for crossmatch testing. Transplantation
typing to immunogenetic profiling. J Transl Med 1(1):8, 2003. 60(12):1594–1599, 1995.
103. LJ K. The study of polymorphism in cytokine and cytokine receptor genes. 126. Christiaans MH, Nieman F, van Hooff JP, et al: Detection of HLA class
2002. I and II antibodies by ELISA and complement-dependent cytotoxic-
104. McCarron SL, Edwards S, Evans PR, et al: Influence of cytokine gene ity before and after transplantation. Transplantation 69(5):917–927,
polymorphisms on the development of prostate cancer. Cancer Res 2000.
62(12):3369–3372, 2002. 127. Marrari MDR: Interlaboratory comparisons of serum screening for
105. Howell WM, Turner SJ, Bateman AC, et al: IL-10 promoter poly- HLA antibody determination and crossmatching by ELISA and flow
morphisms influence tumour development in cutaneous malignant cytometry methods. In. Hum Immunol 2002.
melanoma. Genes Immun 2(1):25–31, 2001. 128. Pei R, Lee J, Chen T, et al: Flow cytometric detection of HLA antibod-
106. Bodmer WF: HLA: what’s in a name? A commentary on HLA nomen- ies using a spectrum of microbeads. Hum Immunol 60(12):1293–1302,
clature development over the years. Tissue Antigens 49(3 Pt 2):293–296, 1999.
1997. 129. Moses LA, Stroncek DF, Cipolone KM, et al: Detection of HLA
107. Tiercy JM, Marsh SG, Schreuder GM, et al: Guidelines for nomencla- antibodies by using flow cytometry and latex beads coated with HLA
ture usage in HLA reports: ambiguities and conversion to serotypes. antigens. Transfusion 40(7):861–866, 2000.
Eur J Immunogenet 29(3):273–274, 2002. 130. Duquesnoy RJ, Marrari M: HLAMatchmaker: a molecularly based
108. Dupont B: Nomenclature for factors of the HLA system, 1987. algorithm for histocompatibility determination. II. Verification of the
Decisions of the Nomenclature Committee on Leukocyte Antigens, algorithm and determination of the relative immunogenicity of amino
which met in New York on November 21-23, 1987. Hum Immunol acid triplet-defined epitopes. Hum Immunol 63(5):353–363, 2002.
26(1):3–14, 1989. 131. Rotzschke O, Falk K, Stevanovic S, et al: Peptide motifs of closely
109. Robinson J, Mistry K, McWilliam H, et al: The IMGT/HLA database. related HLA class I molecules encompass substantial differences. Eur J
Nucleic Acids Res 39(Database issue):D1171–D1176, 2011. Immunol 22(9):2453–2456, 1992.
110. Shilling HG, Guethlein LA, Cheng NW, et al: Allelic polymorphism 132. Parker KC, Bednarek MA, Hull LK, et al: Sequence motifs important
synergizes with variable gene content to individualize human KIR for peptide binding to the human MHC class I molecule, HLA-A2. J
genotype. J Immunol 168(5):2307–2315, 2002. Immunol 149(11):3580–3587, 1992.
111. Turner D, Choudhury F, Reynard M, et al: Typing of multiple single 133. Sette A, Vitiello A, Reherman B, et al: The relationship between class
nucleotide polymorphisms in cytokine and receptor genes using SNaP- I binding affinity and immunogenicity of potential cytotoxic T cell
shot. Hum Immunol 63(6):508–513, 2002. epitopes. J Immunol 153(12):5586–5592, 1994.
112. Svejgaard A, Ryder LP: HLA and disease associations: detecting the 134. Bunce M, O’Neill CM, Barnardo MC, et al: Phototyping: compre-
strongest association. Tissue Antigens 43(1):18–27, 1994. hensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5
113. Boisgerault F, Khalil I, Tieng V, et al: Definition of the HLA-A29 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific
peptide ligand motif allows prediction of potential T-cell epitopes primers (PCR-SSP). Tissue Antigens 46(5):355–367, 1995.
from the retinal soluble antigen, a candidate autoantigen in birdshot 135. Krausa P, Browning MJ: A comprehensive PCR-SSP typing system for
retinopathy. Proc Natl Acad Sci USA 93(8):3466–3470, 1996. identification of HLA-A locus alleles. Tissue Antigens 47(3):237–244,
114. Cope AP, Patel SD, Hall F, et al: T cell responses to a human cartilage 1996.
autoantigen in the context of rheumatoid arthritis-associated and 136. Itoh Y, Mizuki N, Shimada T, et al: High-throughput DNA typing of
nonassociated HLA-DR4 alleles. Arthritis Rheum 42(7):1497–1507, HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in
1999. the Japanese population. Immunogenetics 57(10):717–729, 2005.
115. Friday RP, Trucco M, Pietropaolo M: Genetics of Type 1 diabetes 137. Ng J, Hurley CK, Carter C, et al: Large-scale DRB and DQB1 oligo-
mellitus. Diabetes Nutr Metab 12(1):3–26, 1999. nucleotide typing for the NMDP registry: progress report from year 2.
116. Luppi P, Alexander A, Bertera S, et al: The same HLA-DQ alleles Tissue Antigens 47(1):21–26, 1996.
determine either susceptibility or resistance to different coxsackievirus- 138. Bettinotti MMF HLA and cancer: Immunogenetics in action. 2001.
mediated autoimmune diseases. J Biol Regul Homeost Agents 13(1):14–26, 139. Adams SD, Barracchini KC, Simonis TB, et al: High throughput HLA
1999. sequence-based typing (SBT) utilizing the ABI Prism 3700 DNA
117. Luppi P, Rossiello MR, Faas S, et al: Genetic background and environ- Analyzer. Tumori 87(2):S40–S43, 2001.
ment contribute synergistically to the onset of autoimmune diseases. J 140. Adams SDKP, McGinniss MH Practicality of high-throughput HLA
Mol Med 73(8):381–393, 1995. sequencing based typing. 2001;Sect. 45.
118. Jongeneel CV, Briant L, Udalova IA, et al: Extensive genetic poly- 141. McGinniss MHSJ, Adams SD: Implementing high throughput HLA
morphism in the human tumor necrosis factor region and relation to SBT on a 96-capillary DNA sequencer. In. Hum Immunol 2001.
extended HLA haplotypes. Proc Natl Acad Sci USA 88(21):9717–9721, 142. Adams SD, Barracchini KC, Chen D, et al: Ambiguous allele combina-
1991. tions in HLA Class I and Class II sequence-based typing: when precise